Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger’s Novel Early Cancer Detection Platform
CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection. The Cancer ORigin Epigenetics- Harbinger Health (CORE-HH) study plans … [Read more…]
